Benefits of D-005, a lipid extract from Acrocomia crispa fruits, in the prevention of acute kidney njury induced by nephrotoxicity in rats.


Journal

Jornal brasileiro de nefrologia
ISSN: 2175-8239
Titre abrégé: J Bras Nefrol
Pays: Brazil
ID NLM: 9426946

Informations de publication

Date de publication:
Historique:
received: 01 03 2021
accepted: 12 05 2021
pubmed: 22 7 2021
medline: 24 3 2022
entrez: 21 7 2021
Statut: ppublish

Résumé

Aminoglycoside-induced acute kidney injury (AKI) is a pathology closely linked to oxidative and inflammatory reactions. Taking into account the previous reported antioxidant and anti-inflammatory effects of D-005, a lipid extract obtained from Cuban palm Acrocomia crispa (Arecaceae) fruits, this work aimed to evaluate the effects of D-005 on kanamycin-induced AKI. Male Wistar rats were divided into 7 groups: negative control (vehicle, Tween 65/H2O) and six groups treated with kanamycin to induce AKI: positive control (vehicle), D-005 (25, 100, 200, and 400 mg/kg) and grape seed extract (GSE, 200 mg/kg). D-005, vehicle, and GSE oral treatments were administered once daily for seven days, 1 h before kanamycin (500 mg/kg, i.p.). Serum uric acid and urea concentrations, renal histopathology, and oxidative markers (malondialdehyde (MDA), sulfhydryl (SH) groups, and catalase (CAT) activity) were assessed. D-005 significantly reduced uric acid and urea levels, starting from D-005 100 mg/kg. Histopathologically, D-005, at all the tested doses, protected renal parenchyma structures (glomeruli, proximal tubules, and interstitium). These findings were accompanied by a significant reduction of MDA and SH group concentrations as well as restoration of CAT activity. The highest percentages of inhibition were obtained with the dose of 400 mg/kg. GSE, the reference substance, also prevented kanamycin-induced biochemical and histopathological changes, as well as reduced MDA and SH groups and restored CAT activity. The administration of repeated oral doses of D-005 significantly protected against kanamycin-induced AKI, which could be associated with the antioxidant and anti-inflammatory effects of this extract.

Identifiants

pubmed: 34289007
pii: S0101-28002021005058301
doi: 10.1590/2175-8239-JBN-2021-0048
pmc: PMC8943882
pii:
doi:

Substances chimiques

Antioxidants 0
Lipids 0
Uric Acid 268B43MJ25
Malondialdehyde 4Y8F71G49Q

Types de publication

Journal Article

Langues

eng por

Sous-ensembles de citation

IM

Pagination

9-18

Références

Kidney Int. 2011 Jan;79(1):33-45
pubmed: 20861826
Integr Biol (Camb). 2011 Sep;3(9):879-86
pubmed: 21799993
Ren Fail. 2012;34(2):227-34
pubmed: 22263836
Anal Biochem. 1978 Jun 15;87(1):206-10
pubmed: 98070
Biomed Pharmacother. 2017 Jan;85:128-135
pubmed: 27930976
Zool Res. 2018 Mar 18;39(2):72-86
pubmed: 29515089
Toxicology. 2017 Jun 15;385:10-17
pubmed: 28472626
Kidney Res Clin Pract. 2019 Dec 31;38(4):462-471
pubmed: 31826388
Expert Opin Drug Saf. 2020 Feb;19(2):167-186
pubmed: 31914328
Ren Fail. 2011;33(8):824-32
pubmed: 21787152
Nutrients. 2017 Jul 07;9(7):
pubmed: 28686196
Pharmacology. 2003 Mar;67(3):118-20
pubmed: 12571406
J Bras Nefrol. 2020 Jul-Sep;42(3):290-299
pubmed: 32720969
Biomed Res Int. 2017;2017:5605634
pubmed: 28744467
Iran J Kidney Dis. 2019 Jan;13(1):10-20
pubmed: 30851714
Anal Biochem. 1979 Jun;95(2):351-8
pubmed: 36810
Mol Med Rep. 2014 Mar;9(3):801-7
pubmed: 24399449
Toxicology. 2017 Feb 15;377:14-24
pubmed: 27940129
Naunyn Schmiedebergs Arch Pharmacol. 2015 Dec;388(12):1305-15
pubmed: 26272642
Bratisl Lek Listy. 2017;118(4):233-242
pubmed: 28471235
Res Exp Med (Berl). 2000 Feb;199(4):195-206
pubmed: 10743677
J Am Soc Nephrol. 2015 Aug;26(8):1765-76
pubmed: 25810494
Clin Kidney J. 2016 Feb;9(1):48-50
pubmed: 26798460
Cell Mol Biol (Noisy-le-grand). 2018 Nov 30;64(14):108-113
pubmed: 30511629
Acta Med Iran. 2013;51(12):871-8
pubmed: 24442542
EXCLI J. 2017 Mar 24;16:388-399
pubmed: 28507482
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Basic Clin Pharmacol Toxicol. 2006 Sep;99(3):230-6
pubmed: 16930296
Methods Enzymol. 1994;233:380-5
pubmed: 8015473

Auteurs

Sandra Rodríguez-Salgueiro (S)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.
Facultad Latinoamericana de Medicina, Departamento de Ciencias Morfológicas, Havana, Cuba.

Leyanis Ocaña-Nápoles (L)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.

Ambar Oyarzábal-Yera (A)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.

Lucía González-Núñez (L)

Facultad Latinoamericana de Medicina, Departamento de Ciencias Morfológicas, Havana, Cuba.

Giselle Breña-Betancourt (G)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.

María Flavia Pérez-Pino (MF)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.

José A Medina-Pírez (JA)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.

Sonia Jiménez-Despaigne (S)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.

Vivian Molina-Cuevas (V)

Centro Nacional de Investigación Científica, Departamento de Farmacología, Havana, Cuba.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH